RE: Exciting Times11 Sep 2021 16:51
Part1
As far as taking a drug to market , I'd say Faron are better positioned or experienced to know how to do it , only in as much as they were gearing up in 2018 with Traumakine , and had a plan . They hired a Chief Commercial Officer , about 5 months before P3 data was due , whose role was to execute the launch of the drug , along with engaging the services of another US company that specialised in drug launches ( can't find their name )
From an RNS in early 2018 -
In preparation for the Traumakine global launch, the Company wishes to raise capital to accelerate the build out of medical sales and supply chain logistics.
· In particular, the Company intends to build a strong US sales and marketing base in Boston and create a logistics network to enhance US market entrance including an early access program.
· This will allow the Company to initiate the alternative of a direct sales model in the US and EU as a route to market, with the opportunity to retain more profits, in addition to out-licensing.
So back then , they were actively engaged in giving themselves the opportunity to set up direct selling , along with licensing for other parts of the world .
The Traumakine P3 now is majorly funded by DofD , so if that trial comes good , who knows what the tie up will be . They have the base in Boston , which looks as though it may become more important as the business focus certainly seems more US based recently .
Then we have Bex , which could seriously dwarf the numbers that Traumakine was going to produce .
Licensing / selling parts on that seems much more likely as it seems to be a therapy that could be more easily sliced up.
Markku talked of the Keytruda opportunity ( doubling the effectiveness of a $14 billion a year drug ) - has to be worth a couple of billion you'd think minimum ?
And then all the solid tumour cohorts , each one a possible goldmine .
Soluble Clever-1 - that could be the key to making Bex's effectiveness multiples of what it already is - it's just we don't know that yet - perhaps Friday ?
50 million shares and a £211m Mcap - £4.22
Room to multiply the Mcap by 5-10 easily with a successful deal . But i don't see it happening in the next month or two .
Faron have had plenty of years to work out their best next steps . I don't see a full sale of either drug , and the biggest targets ( new trials) are still to get underway . So the true value is still unknown , could be multiple deals down the road .
This all just musings , but given the continued success in trials , I see the Faron Mcap growing in leaps , as further trials produce deal opportunities.
Sign In
Follow the stocks
